Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX5UKA)

Drug Name

PMID22115617C2c Drug Info

Synonyms

TMCB; 905105-89-7; TMCB/; GTPL8140; DTXSID50677589; MolPort-019-939-193; BS0265; BDBM50359846; ZINC58638742; ABP000318; AKOS024457742; K66

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Casein kinase II alpha (CSNK2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CX-4945	DMWE7B9	Coronavirus infection	1D92	Phase 2	[2]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[3]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[4]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[5]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[4]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[4]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[4]
PMID24900749C1a	DMZPUSO	Discovery agent	N.A.	Investigative	[6]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[7]
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	DM3JB6S	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Casein kinase II alpha prime (CSNK2A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US8940736, 6	DMXY4SP	N. A.	N. A.	Patented	[8]
US8940736, 23	DM3PU57	N. A.	N. A.	Patented	[8]
US8791257, 38	DMAEHCP	N. A.	N. A.	Patented	[9]
US8791257, 4	DMIQO8N	N. A.	N. A.	Patented	[9]
US8791257, 17	DMUPRX2	N. A.	N. A.	Patented	[9]
US8940736, 7	DM9KSVI	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase II alpha (CSNK2A1)	TTER6YH	CSK21_HUMAN	Inhibitor	[1]
Casein kinase II alpha prime (CSNK2A2)	TTR93NU	CSK22_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
4	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
5	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
6	Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
7	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
8	Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736.
9	Substituted pyrrolotriazines as protein kinase inhibitors. US8791257.